At Jazz, our purpose is to innovate to transform the lives of patients and their families. There is no better example of this objective than our presence at SLEEP 2022, the 36th annual meeting of the Associated Professional Sleep Societies.
The 17 new abstracts to be presented at the meeting showcase our rapidly expanding neuroscience pipeline and portfolio. While this number of data presentations clearly demonstrates our leadership and our commitment to expanding research in sleep medicine, I am more excited about the potential for those living with these debilitating conditions.
For decades, Jazz has prioritized the lives of those living with these disorders and been a pioneer in sleep medicine and therapies. Across narcolepsy and idiopathic hypersomnia (IH), we have prioritized developing new medicines to benefit people with limited or no treatment options.
We take pride in developing first-of-its-kind treatments for patients that set new standards of care. As a company, we push ourselves to think holistically about patients’ health, which is why we aspire to develop next-generation therapies that address the needs of other sleep disorders.
To address the low understanding of idiopathic hypersomnia, Jazz partnered with the Hypersomnia Foundation last year to launch I Have IH, a disease awareness campaign aimed at increasing knowledge of idiopathic hypersomnia and encouraging those who may be struggling with the sleep disorder to have effective discussions with their healthcare providers. As part of the campaign, Jazz and the Hypersomnia Foundation surveyed healthcare providers, people with idiopathic hypersomnia and those who care for them to measure each group’s perceptions and knowledge of idiopathic hypersomnia. As part of the next evolution of the campaign, Jazz is proud to present two posters at SLEEP 2022 with the results of these surveys. We are excited to share these findings with the exact doctors who can help change the perception, understanding and awareness of this debilitating condition.
We continue to be pioneers in sleep medicine, building on the momentum we have had in narcolepsy and idiopathic hypersomnia, reinforcing our passion for advancing research, elevating patient voices and addressing unmet needs through our transformational medicines. For more information on Jazz’s presence at SLEEP 2022, follow along on Jazz’s Twitter and LinkedIn channels.
الإبلاغ عن أثر جانبي
إذا كنت ترغب في الإبلاغ عن أثر جانبي مرتبط بالمنتجات الدوائية لشركة Jazz Pharmaceuticals، يُرجى إرسال بريد إلكتروني إلينا عبر الرابط التالي:
يُرجى تقديم أكبر قدر ممكن من المعلومات المتاحة.
تشمل المعلومات ذات الصلة ما يلي:
بتقديمك لتقريرك وتزويدنا ببيانات الاتصال الخاصة بك، فإنك تُقرّ وتوافق صراحةً على أنه يجوز لقسم السلامة الدوائية المحلي التواصل معك بغرض طلب معلومات إضافية أو توضيحات، إذا اعتُبر ذلك ضروريًا لتقييم التقرير ومتابعته.
يوضح إشعار الخصوصية الخاص بنا المتعلق باليقظة الدوائية والمعلومات الطبية وشكاوى المنتجات كيفية تعامل شركة Jazz Pharmaceuticals مع معالجة المعلومات الشخصية عند التعامل مع تقريرالأثر الجانبي الخاص بك، وهو متاح في مركز الخصوصية لدينا.
Report an Adverse Event
If you want to report a Adverse Event related to Jazz Pharmaceuticals medicinal products, then please send us an e-mail via this link:
Please provide as much available information as possible.
Relevant information includes:
By submitting your report and providing your contact details, you expressly acknowledge and agree that the local drug safety department may contact you for the purpose of requesting additional information or clarifications, should this be deemed necessary for the assessment and follow‑up of the report.
Our Privacy Notice for Pharmacovigilance, Medical Information and Product Complaints outlines how Jazz Pharmaceuticals handles the processing of personal information when dealing with your adverse event report and is available in our Privacy Center.
